|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.290 USD | -0.77% |
|
+8.40% | -63.46% |
| 06-30 | ADC Therapeutics SA Completes Enrollment In LOTIS-7 Phase 1b ZYNLONTA Combination Trial | CI |
| 06-30 | ADC Therapeutics Completes Enrollment in LOTIS-7 Lymphoma Study | MT |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Bearish | Bearish |
| Resistance | 1.85 | 2.12 | 2.13 |
| Spread/Res. | -30.27% | -39.15% | -39.44% |
| Spread/Supp. | +31.94% | +31.94% | +26.47% |
| Support | 0.9777 | 0.9777 | 1.02 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- ADCT Stock
- Charts ADC Therapeutics SA
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
